- RecruitingPHASE2, PHASE3
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
This study is looking at a new medicine called tividenofusp alfa for children and young adults with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. It compares the new medicine to a standard treatment, idursulfase, to see if it's safe and works well.
For: Mucopolysaccharidosis IIUnited States · Argentina · Australia - Enrolling by invitationPHASE2, PHASE3
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
This study is looking at the long-term safety and effectiveness of a new medicine, tividenofusp alfa, for children with Hunter syndrome (MPS II). It's an extension for those who have already been in similar studies.
For: Mucopolysaccharidosis IIUnited States · Argentina · Belgium - Active not recruitingPHASE1, PHASE2
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
This study is testing a new medicine called tividenofusp alfa for children and young people with Hunter syndrome. It aims to see if the medicine is safe and how it works in the body to help with both physical and brain symptoms of the condition.
For: Mucopolysaccharidosis IIUnited States · Canada · Netherlands